Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
The New England Journal of Medicine
|
October 22, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
Thomas Powles, Ariel G Kann, Daniel Castellano, et al.
International Journal of Clinical Oncology
|
May 23, 2021
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.
Journal of Cancer Research and Clinical Oncology
|
September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
European Urology Focus
|
October 3, 2020
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.
BMC Cancer
|
November 22, 2025
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program
Mehmet Ali Nahit Sendur, Mutlu Hizal, Burcu Çakar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Cancer Research and Clinical Oncology
|
June 10, 2022
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
Mustafa Gürbüz, Yasin Kutlu, Erman Akkuş, et al.
Journal of Cancer Research and Clinical Oncology
|
April 6, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, et al.
Journal of Cancer Research and Clinical Oncology
|
April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Future Oncology (London, England)
|
June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study
Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
The New England Journal of Medicine
|
October 22, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
Thomas Powles, Ariel G Kann, Daniel Castellano, et al.
International Journal of Clinical Oncology
|
May 23, 2021
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.
Journal of Cancer Research and Clinical Oncology
|
September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
European Urology Focus
|
October 3, 2020
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.
BMC Cancer
|
November 22, 2025
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program
Mehmet Ali Nahit Sendur, Mutlu Hizal, Burcu Çakar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Cancer Research and Clinical Oncology
|
June 10, 2022
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
Mustafa Gürbüz, Yasin Kutlu, Erman Akkuş, et al.
Journal of Cancer Research and Clinical Oncology
|
April 6, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, et al.
Journal of Cancer Research and Clinical Oncology
|
April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Future Oncology (London, England)
|
June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study
Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Page
of 6